Ganoderic acid C1CAS# 95311-97-0 |
- Ganoderic acid D
Catalog No.:BCN2437
CAS No.:108340-60-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 95311-97-0 | SDF | Download SDF |
| PubChem ID | 471004 | Appearance | Powder |
| Formula | C30H42O7 | M.Wt | 514.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,6R)-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | ||
| SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(CC(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C | ||
| Standard InChIKey | YTVGSCZIHGRVAV-NJNFCIENSA-N | ||
| Standard InChI | InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,32H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,28+,29-,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Ganoderic acid C1 inhibits histamine release. 2. Ganoderic acid C1 has anti-tumor-promoting activity. 3. Ganoderic acid C1 is moderately active inhibitors against HIV-1 protease. 4. Ganoderic acid C1 has anti-inflammatory activity, has potential for treating TNF-α mediated inflammation in asthma and other inflammatory diseases. |
| Targets | NF-kB | MAPK | AP-1 | TNF-α | IFN-γ | IL Receptor | HIV |
Ganoderic acid C1 Dilution Calculator
Ganoderic acid C1 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9429 mL | 9.7144 mL | 19.4288 mL | 38.8576 mL | 48.572 mL |
| 5 mM | 0.3886 mL | 1.9429 mL | 3.8858 mL | 7.7715 mL | 9.7144 mL |
| 10 mM | 0.1943 mL | 0.9714 mL | 1.9429 mL | 3.8858 mL | 4.8572 mL |
| 50 mM | 0.0389 mL | 0.1943 mL | 0.3886 mL | 0.7772 mL | 0.9714 mL |
| 100 mM | 0.0194 mL | 0.0971 mL | 0.1943 mL | 0.3886 mL | 0.4857 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lucidenic acid C
Catalog No.:BCN7970
CAS No.:95311-96-9
- Lucidenic acid A
Catalog No.:BCN2715
CAS No.:95311-94-7
- Kajiichigoside F1
Catalog No.:BCN6433
CAS No.:95298-47-8
- Yadanzioside G
Catalog No.:BCN6716
CAS No.:95258-17-6
- Yadanzioside C
Catalog No.:BCN6717
CAS No.:95258-16-5
- Yadanzioside A
Catalog No.:BCN6718
CAS No.:95258-15-4
- Yadanziolide A
Catalog No.:BCN6721
CAS No.:95258-14-3
- Yadanziolide B
Catalog No.:BCN6720
CAS No.:95258-13-2
- Yadanziolide C
Catalog No.:BCN6719
CAS No.:95258-12-1
- Yadanzioside F
Catalog No.:BCN6406
CAS No.:95258-11-0
- Hydrangenoside A dimethyl acetal
Catalog No.:BCN4553
CAS No.:952485-00-6
- 11-Oxomogroside III
Catalog No.:BCN3169
CAS No.:952481-53-7
- 2-Hydroxy-5-(2-hydroxy-4-methoxybenzyl)-4-methoxybenzaldehyde
Catalog No.:BCN7769
CAS No.:953427-66-2
- Hainanmurpanin
Catalog No.:BCN4503
CAS No.:95360-22-8
- BLZ945
Catalog No.:BCC5583
CAS No.:953769-46-5
- 15-Hydroxy-7-oxodehydroabietic acid
Catalog No.:BCN4504
CAS No.:95416-25-4
- Neotuberostemonone
Catalog No.:BCN4505
CAS No.:954379-68-1
- Hydroxytuberosone
Catalog No.:BCN4552
CAS No.:95456-43-2
- 5-Hydroxy-7-acetoxy-8-methoxyflavone
Catalog No.:BCN4506
CAS No.:95480-80-1
- 10Panx
Catalog No.:BCC1245
CAS No.:955091-53-9
- 8,3'-Diprenylapigenin
Catalog No.:BCN6482
CAS No.:955135-37-2
- MK-1775
Catalog No.:BCC2543
CAS No.:955365-80-7
- PI-3065
Catalog No.:BCC5379
CAS No.:955977-50-1
- NS 11021
Catalog No.:BCC6290
CAS No.:956014-19-0
Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-kappaB Signaling.[Pubmed:25993687]
Inflamm Bowel Dis. 2015 Aug;21(8):1918-25.
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract. Current medications have potentially serious side effects. Hence, there is increasing interest in alternative therapies. We previously demonstrated the anti-inflammatory effects of Food Allergy Herbal Formula-2 in vitro on peripheral blood mononuclear cells (PBMCs) and mucosa from CD subjects. Here, we investigated the anti-inflammatory effects of a bioactive compound isolated from Ganoderma lucidum (G. lucidum), a key herbal constituent of Food Allergy Herbal Formula-2, in CD in vitro. METHODS: Triterpene Ganoderic acid C1 (GAC1) was isolated from G. lucidum. Stimulated RAW 264.7 macrophages were treated with GAC1. Human PBMCs and colonic biopsies were obtained from children with CD and cultured with or without GAC1. TNF-alpha and other proinflammatory cytokine levels were measured in the culture supernatant. NF-kappaB signaling was investigated in PBMCs and colonic mucosa treated with GAC1 by In-Cell Western and Western blot analysis. RESULTS: GAC1 decreased TNF-alpha production by macrophages and PBMCs from CD subjects. GAC1 significantly decreased TNF-alpha, IFN-gamma, and IL-17A production by inflamed colonic biopsies from CD subjects. These effects were due to downregulation of the NF-kappaB signaling pathway. CONCLUSIONS: GAC1 inhibited production of TNF-alpha and other proinflammatory cytokines by PBMCs and inflamed CD colonic mucosa due to blockage of NF-kappaB activation. GAC1 is a key beneficial constituent in G. lucidum and the Food Allergy Herbal Formula-2 in suppressing the inflammatory cytokines found in CD and warrants clinical investigation for the treatment of CD.
Ganoderic acid C1 isolated from the anti-asthma formula, ASHMI suppresses TNF-alpha production by mouse macrophages and peripheral blood mononuclear cells from asthma patients.[Pubmed:26004313]
Int Immunopharmacol. 2015 Aug;27(2):224-31.
Asthma is a heterogeneous airway inflammatory disease, which is associated with Th2 cytokine-driven inflammation and non-Th2, TNF-alpha mediated inflammation. Unlike Th2 mediated inflammation, TNF-alpha mediated asthma inflammation is generally insensitive to inhaled corticosteroids (ICS). ASHMITM, aqueous extract of three medicinal herbs-Ganoderma lucidum (G. lucidum), Sophora flavescens Ait (S. flavescens) and Glycyrrhiza uralensis Fischer (G. uralensis), showed a high safety profile and was clinically beneficial in asthma patients. It also suppresses both Th2 and TNF-alpha associated inflammation in murine asthma models. We previously determined that G. uralensis flavonoids are the key active compounds responsible for ASHMITM suppression of Th2 mediated inflammation. Until now, there are limited studies on anti-TNF-alpha compounds presented in ASHMITM. The objective of this study was to isolate and identify TNF-alpha inhibitory compounds in ASHMITM. Here we report that G. lucidum, but not the other two herbal extracts, S. flavescens or G. uralensis inhibited TNF-alpha production by murine macrophages; and that the methylene chloride (MC)-triterpenoid-enriched fraction, but not the polysaccharide-enriched fraction, contained the inhibitory compounds. Of the 15 triterpenoids isolated from the MC fraction, only Ganoderic acid C1 (GAC1) significantly reduced TNF-alpha production by murine macrophages (RAW 264.7 cells) and peripheral blood mononuclear cells (PBMCs) from asthma patients. Inhibition was associated with down-regulation of NF-kappaB expression, and partial suppression of MAPK and AP-1 signaling pathways. Ganoderic acid C1 may have potential for treating TNF-alpha mediated inflammation in asthma and other inflammatory diseases.
